Aarti Pharmalabs Announces 7th AGM on Sept 22, 2026, Encloses Annual Report FY26
Aarti Pharmalabs will hold its 7th Annual General Meeting on September 22, 2026, via video conference. The company has released its Annual Report for FY 2025-26, detailing its business segments, investments in capacity and R&D, and sustainability initiatives. The report is available on the company's website.
The announcement is a standard corporate event (AGM) and the release of an annual report. It does not contain new material information such as financial results, significant business changes, or strategic announcements that would have a high impact on the stock price.
The announcement is a routine corporate disclosure regarding the AGM and the release of the annual report. It does not contain any specific financial performance data or strategic decisions that would indicate a positive or negative sentiment.
Aarti Pharmalabs Limited has announced its 7th Annual General Meeting (AGM) scheduled to be held on Tuesday, September 22, 2026, at 11:00 a.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM) without the physical presence of shareholders.
Along with the notice of the AGM, the company has also enclosed the Annual Report for the Financial Year 2025-26. Both documents are being sent electronically to shareholders whose email addresses are registered with the company or with their Depository Participants, in accordance with MCA and SEBI circulars. For shareholders whose email addresses are not registered, the company is sending letters containing a web link to the Annual Report. The Annual Report and AGM notice are also available on the company's website at https://www.aartipharmalabs.com/annual-reports.
The Annual Report for FY 2025-26 details various aspects of the company's operations, including its journey, business segments (Xanthine Derivatives and Allied Products, API and Intermediates, CDMO and CMO), manufacturing and R&D infrastructure, operating environment, chairman's message, managing directors' message, and financial statements. It highlights the company's investments in capacity expansion, scientific capabilities, and technology, positioning it for future growth, particularly in the CDMO segment. The report also mentions the company's commitment to sustainability and responsible growth, including its EcoVadis Gold Rating and SBTi-approved emission reduction targets.
A plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.